Search Result

Results for "

53155 25 2 cxcr Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CXCR (168) Akt (1) Apelin Receptor (APJ) (3) Apoptosis (8) Arrestin (3) Biochemical Assay Reagents (1) CCR (4) CX3CR1 (1) DNA/RNA Synthesis (1) Drug Metabolite (2) Drug-Linker Conjugates for ADC (2) Endogenous Metabolite (7) Fluorescent Dye (1) Formyl Peptide Receptor (FPR) (1) Fungal (2) GPR35 (6) HIF/HIF Prolyl-Hydroxylase (1) HIV (28) iGluR (4) Interleukin Related (3) Isotope-Labeled Compounds (2) Microtubule/Tubulin (2) Opioid Receptor (1) Oxidative Phosphorylation (1) P2X Receptor (1) PI3K (1) Protein Arginine Deiminase (1) Radionuclide-Drug Conjugates (RDCs) (4) Small Interfering RNA (siRNA) (16) STAT (1) Virus Protease (1)
By Research Areas:	Cancer (82) Cardiovascular Disease (5) Endocrinology (56) Infection (39) Inflammation/Immunology (93) Metabolic Disease (2) Neurological Disease (12)
Oligonucleotides:	Pre-designed siRNA Sets (16) siRNAs (16)

195

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: CXCR Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-139643

CXCR7 antagonist-1	CXCR	Inflammation/Immunology Cancer
CXCR7 antagonist-1 is a *CXCR7* antagonist that inhibits the binding of the SDF-1 chemokine (also known as the CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CXCR7. CXCR7 antagonist-1 is useful in preventing tumor cell proliferation, tumor formation, inflammatory diseases, and many other diseases (extracted from patent WO2014085490A1, compound 1.128) .

HY-139643A

CXCR7 antagonist-1 hydrochloride	CXCR	Inflammation/Immunology Cancer
CXCR7 antagonist-1 hydrochloride is a *CXCR7* antagonist that inhibits the binding of the SDF-1 chemokine (also known as the CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CXCR7. CXCR7 antagonist-1 hydrochloride is useful in preventing tumor cell proliferation, tumor formation, inflammatory diseases, and many other diseases (extracted from patent WO2014085490A1, compound 1.128) .

HY-P990254

*Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173)*	CXCR	Others
Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse CXCR3/CD183.

HY-120878

CXCR2-IN-2 1 Publications Verification	CXCR	Inflammation/Immunology
CXCR2-IN-2 is a selective, brain penetrant, and orally bioavailable *CXCR2* antagonist (IC₅₀=5.2 nM/1 nM in β-arrestin assay/CXCR2 Tango assay, respectively). CXCR2-IN-2 displays ~730-fold selectivity over CXCR1 and >1900-fold selectivity over all other chemokine receptors. CXCR2-IN-2 inhibits human whole blood Gro-α induced CD11b expression with an IC₅₀ of 0.04 μM .

HY-101022

CXCR2-IN-1 2 Publications Verification	CXCR	Inflammation/Immunology Endocrinology
CXCR2-IN-1 is a central nervous system penetrant *CXCR2* antagonist with a pIC₅₀ of 9.3.

HY-161735

CXCR4-IN-3	CXCR	Inflammation/Immunology
CXCR4-IN-3 (compound XVI) is an orally active and potent inhibitor targeting the inflammation-related receptor *CXCR4, with an IC₅₀* of 3.2 nM. CXCR4-IN-3 exhibits potent antichemotactic activity, at 79.19±2.33% inhibition. CXCR4-IN-3 shows anti-inflammatory activity. CXCR4-IN-3 can be used for IBD (inflammatory bowel disease) research .

HY-153464

CXCR4-IN-1	CXCR	Infection Cardiovascular Disease Inflammation/Immunology Cancer
CXCR4-IN-1 (Example C5) is a *CXCR4* inhibitor (IC₅₀: 20 nM). CXCR4-IN-1 can be used for research of cancer, HIV, diabetic retinopathy, inflammation, etc .

HY-149558

CXCR4-IN-2	Apoptosis CXCR	Cancer
CXCR4-IN-2 (compound A1) is a bifunctional fluorinated small molecule that is a potent CXCR4 inhibitor with anticancer activity. CXCR4-IN-2 has cytotoxic (IC₅₀: 60 μg/mL; 72 h) and antiproliferative effects on mouse colorectal cancer (CRC) cells. CXCR4-IN-2 induces cell arrest in the G2/M phase and induces apoptosis .

HY-P5297

*DOTA-CXCR4-L*	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA-CXCR4-L is a *CXCR4* targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer .

HY-147978

CXCR4 antagonist 8	CXCR	Infection Cancer
CXCR4 antagonist 8 (Compound 3) is a *CXCR4* antagonist with an IC₅₀ of 57 nM. CXCR4 antagonist 8 inhibits CXCL12 induced cytosolic calcium increase with an IC₅₀ of 0.24 nM. CXCR4 antagonist 8 inhibits CXLC12/CXCR4 mediated cell migration .

HY-146053

CXCR4 modulator-1	CXCR	Infection Inflammation/Immunology Cancer
CXCR4 modulator-1 (compound ZINC72372983) is a potent *CXCR4* modulator with an EC₅₀ value of 100 nM. CXCR4 modulator-1 can be used for researching anti-inflammatory, anticancer and anti-HIV .

HY-146401

CXCR4 antagonist 6	CXCR	Cancer
CXCR4 antagonist 6 (compound 46) is a potent *CXCR4* antagonist with an IC₅₀ value of 79 nM. CXCR4 antagonist 6 inhibits CXCL12 induced cytosolic calcium flux (IC₅₀ = 0.25 nM). CXCR4 antagonist 6 significantly mitigates CXCL12/CXCR4 mediated cell migration. CXCR4 antagonist 6 exhibits marked efficacy in a cancer metastasis model in mice .

HY-136437

CXCR4 antagonist 1	CXCR HIV	Infection
CXCR4 antagonist 1 is a potent *CXCR4* antagonist. CXCR4 antagonist 1 has anti-HIV activity .

HY-144286

CXCR4 antagonist 3	CXCR	Infection
CXCR4 antagonist 3 (compound 12a) is a potent antagonist of *CXCR4* with an IC₅₀ of 11 nM. CXCR4 antagonist 3 is a congener of TIQ15. CXCR4 antagonist 3 demonstrates the best overall properties including CXCR4 antagonism, CYP 2D6 inhibition, metabolic stability, and permeability. CXCR4 antagonist 3 has the potential for the research of human immunodeficiency virus .

HY-147392

CXCR2 antagonist 8	CXCR	Metabolic Disease
CXCR2 antagonist 8 is a potent and selective *CXCR2* antagonist. CXCR2 antagonist 8 can be used for insulin resistance research .

HY-132936

CXCR4 antagonist 2	CXCR	Others
CXCR4 antagonist 2 is a *CXCR4* antagonist with an IC₅₀ value of 47 nM.

HY-144784

CXCR2 antagonist 7	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 7 (compound 19) is a potent *CXCR2* antagonist. CXCR2 antagonist 7 shows potent *CXCR2* binding affinity (IC₅₀=0.044 µM) and calcium mobilization (IC₅₀=0.66 µM) ^{[ 1]}.

HY-144781

CXCR2 antagonist 5	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 5 (compound 25) is a potent *CXCR2* antagonist. CXCR2 antagonist 5 shows potent *CXCR2* binding affinity (IC₅₀=0.013 µM) and calcium mobilization (IC₅₀=0.1 µM) ^{[ 1]}.

HY-163475

*CXCL-CXCR1/2-IN-1*	CXCR	Cancer
CXCL-CXCR1/2-IN-1 is an orally active ELR ⁺CXCL-CXCR1/2 pathway inhibitor with an EC₅₀ of 42.7 nM for CXCR2 . CXCL-CXCR1/2-IN-1 shows anticancer and antiangiogenic effects .

HY-168095

CXCR4 antagonist 10	CXCR	Cancer
CXCR4 antagonist 10 (compound 21) is a potent antagonist of *CXCR4, with the IC₅₀* of 7.8 nM. CXCR4 antagonist 10 plays an important role in cancer research .

HY-146372

CXCR4 antagonist 5	CXCR	Cancer
CXCR4 antagonist 5 (compound 23) is a highly potent *CXCR4* antagonist with an IC₅₀ value of 8.8 nM. CXCR4 antagonist 5 can inhibit CXCL12-induced cytosolic calcium increase (IC₅₀ = 0.02 nM) and inhibits CXCR4/CXLC12-mediated chemotaxis. CXCR4 antagonist 5 has good physicochemical properties and in vitro safety profiles, inhibiting CYP isozymes and hERG marginally or moderately .

HY-144783

CXCR2 antagonist 6	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 6 (compound 35c) is a potent *CXCR2* antagonist. CXCR2 antagonist 6 shows potent *CXCR2* binding affinity (IC₅₀=0.044 µM) and calcium mobilization (IC₅₀=0.66 µM) ^{[ 1]}.

HY-139874

CXCR2 antagonist 3	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 3 (compound 11h) is a potent antagonist of CXC chemokine receptor 2 (CXCR2). CXCR2 antagonist 3 demonstrates double-digit nanomolar potencies against CXCR2 and significantly inhibited neutrophil infiltration into the air pouch. CXCR2 antagonist 3 reduces the infiltration of neutrophils and MDSCs and enhance the infiltration of CD3 ⁺ T lymphocytes into the Pan02 tumor tissues .

HY-120878A

*(R,R)-CXCR2-IN-2*	CXCR	Inflammation/Immunology
(R,R)-CXCR2-IN-2, diastereoisomer of CXCR2-IN-2 (compound 68), is a brain penetrant *CXCR2* antagonist with a pIC₅₀ of 9 and 6.8 in the Tango assay and d in the HWB Gro-α induced CD11b expression assay, respectively .

HY-147979

CXCR4 antagonist 9	CXCR	Infection Cancer
CXCR4 antagonist 9 (Compound 2) is a *CXCR4* antagonist with an IC₅₀ of 15 nM. CXCR4 antagonist 9 inhibits CXCL12 induced cytosolic calcium increase with an IC₅₀ of 1.3 nM .

HY-146054

CXCR4 modulator-2	CXCR	Inflammation/Immunology
CXCR4 modulator-2 (compound Z7R) is a highly potent *CXCR4* modulator with an IC₅₀ value of 1.25 nM. CXCR4 modulator-2 has acceptable stability (t_1/2 = 77.1 min) in mouse serum and exhibits anti-inflammatory activity in mouse edema model .

HY-139873

CXCR2 antagonist 2	CXCR	Cancer
CXCR2 antagonist 2 is a potent *CXCR2* antagonist for cancer immunoresearch with an IC₅₀ value of 95 nM.

HY-144780

CXCR2 antagonist 4	CXCR	Cancer
CXCR2 antagonist 4 (compound 7) is a potent *CXCR2* antagonist with an IC₅₀ value of 0.13 μM. CXCR2 antagonist 4 can inhibit CXCL8-induced cytosolic calcium increase (IC₅₀ = 27 μM). CXCR2 antagonist 4 can be used for researching anticancer .

HY-147808

CXCR4 antagonist 7	CXCR HIV	Infection Inflammation/Immunology Cancer
CXCR4 antagonist 7 (Compound PARA-B) is a *CXCR4* antagonist with the IC₅₀ of 9.3 nM. CXCR4 antagonist 7 can be used for the research of HIV infection, inflammatory diseases, cancer, and WHIM syndrome .

HY-112154

CXCR7 modulator 2	CXCR	Cardiovascular Disease Endocrinology
CXCR7 modulator 2 is a modulator of C-X-C Chemokine Receptor Type 7 (CXCR7), with a K_i of 13 nM.

HY-107987

CXCR7 modulator 1	CXCR	Endocrinology
CXCR7 modulator 1 (compound 25) is a potent and orally bioavailable peptoid hybrid *CXCR7* modulator, with a K_i of 9 nM .

HY-P990395

*Anti-CXCR4/CD184 Antibody*	CXCR	Inflammation/Immunology
Anti-CXCR4/CD184 Antibody is a CHO-expressed human antibody that targets *CXCR4/CD184. The Anti-CXCR4/CD184 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCR*4/CD184 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-128063

CXCR3 antagonist 1	CXCR	Inflammation/Immunology
CXCR3 antagonist 1 (compound 6c) is a selective and non-cytotoxic *CXCR3* antagonist (IC₅₀=0.06 µM). CXCR3 antagonist 1 has potential in researching inflammatory diseases (including inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and diabetes) .

HY-D2310

CXCR2 Probe 1	CXCR	Inflammation/Immunology
CXCR2 Probe 1 (Compound ^[18F]16b) is a selective ligand for *CXCR2* and is a radiotracer for PET imaging of neutrophils in inflammatory diseases .

HY-144285

CXCR4 antagonist 4	CXCR HIV	Inflammation/Immunology
CXCR4 antagonist 4 is a potent, orally active *CXCR4* antagonist (IC₅₀=24 nM) with diminished CYP 2D6 activity, improved PAMPA permeability, potent inhibition of human immunodeficiency virus entry (IC₅₀=7 nM) .

HY-RS03397

CXCR1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CXCR1 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CXCR1 Human Pre-designed siRNA Set A CXCR1 Human Pre-designed siRNA Set A

HY-RS03398

Cxcr1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cxcr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cxcr1 Mouse Pre-designed siRNA Set A Cxcr1 Mouse Pre-designed siRNA Set A

HY-RS03399

Cxcr1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cxcr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cxcr1 Rat Pre-designed siRNA Set A Cxcr1 Rat Pre-designed siRNA Set A

HY-RS03400

CXCR2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CXCR2 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CXCR2 Human Pre-designed siRNA Set A CXCR2 Human Pre-designed siRNA Set A

HY-RS03401

Cxcr2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cxcr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cxcr2 Mouse Pre-designed siRNA Set A Cxcr2 Mouse Pre-designed siRNA Set A

HY-RS03402

Cxcr2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cxcr2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcr2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cxcr2 Rat Pre-designed siRNA Set A Cxcr2 Rat Pre-designed siRNA Set A

HY-RS03403

CXCR3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CXCR3 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CXCR3 Human Pre-designed siRNA Set A CXCR3 Human Pre-designed siRNA Set A

HY-RS03404

Cxcr3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cxcr3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cxcr3 Mouse Pre-designed siRNA Set A Cxcr3 Mouse Pre-designed siRNA Set A

HY-RS03405

Cxcr3 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cxcr3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcr3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cxcr3 Rat Pre-designed siRNA Set A Cxcr3 Rat Pre-designed siRNA Set A

HY-RS03406

CXCR4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CXCR4 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CXCR4 Human Pre-designed siRNA Set A CXCR4 Human Pre-designed siRNA Set A

HY-RS03407

Cxcr4 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cxcr4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cxcr4 Mouse Pre-designed siRNA Set A Cxcr4 Mouse Pre-designed siRNA Set A

HY-RS03408

Cxcr4 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cxcr4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcr4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cxcr4 Rat Pre-designed siRNA Set A Cxcr4 Rat Pre-designed siRNA Set A

HY-RS03409

CXCR5 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CXCR5 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CXCR5 Human Pre-designed siRNA Set A CXCR5 Human Pre-designed siRNA Set A

HY-RS03410

CXCR6 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CXCR6 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CXCR6 Human Pre-designed siRNA Set A CXCR6 Human Pre-designed siRNA Set A

HY-RS03411

Cxcr6 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cxcr6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cxcr6 Mouse Pre-designed siRNA Set A Cxcr6 Mouse Pre-designed siRNA Set A

Cat. No.	Product Name

HY-L031

Small Molecule Immuno-Oncology Compound Library

572 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 572 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Cat. No.	Product Name	Type

HY-D2310

CXCR2 Probe 1	Dyes
CXCR2 Probe 1 (Compound ^[18F]16b) is a selective ligand for *CXCR2* and is a radiotracer for PET imaging of neutrophils in inflammatory diseases .

Cat. No.	Product Name	Target	Research Area

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective *CXCR4* antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-12488

LY2510924 Maximum Cited Publications 12 Publications Verification	CXCR	Endocrinology Cancer
LY2510924 is a potent and selective *CXCR4* antagonist that blocks SDF-1 binding to CXCR4 with an IC₅₀ of 0.079 nM.

HY-P1102

TC14012 2 Publications Verification	CXCR HIV	Infection Cancer
TC14012, a serum-stable derivative of T140, is a selective and peptidomimetic *CXCR4* antagonist with an IC₅₀ of 19.3 nM. TC14012 is a potent *CXCR7* agonist with an EC₅₀ of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 has anti-HIV activity and anti-cancer activity .

HY-P1104A

FC131 TFA	CXCR HIV	Infection
FC131 TFA is a *CXCR4* antagonist, inhibits [ ¹²⁵I]-SDF-1 binding to CXCR4, with an IC₅₀ of 4.5 nM. Anti-HIV activity .

HY-P5297

*DOTA-CXCR4-L*	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA-CXCR4-L is a *CXCR4* targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer .

HY-168095

CXCR4 antagonist 10	CXCR	Cancer
CXCR4 antagonist 10 (compound 21) is a potent antagonist of *CXCR4, with the IC₅₀* of 7.8 nM. CXCR4 antagonist 10 plays an important role in cancer research .

HY-144285

CXCR4 antagonist 4	CXCR HIV	Inflammation/Immunology
CXCR4 antagonist 4 is a potent, orally active *CXCR4* antagonist (IC₅₀=24 nM) with diminished CYP 2D6 activity, improved PAMPA permeability, potent inhibition of human immunodeficiency virus entry (IC₅₀=7 nM) .

HY-P2218

Anditixafortide	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a *CXCR4-targeting* peptide derivative .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective *CXCR4* antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P4810

Polyphemusin II-Derived Peptide T140	CXCR	Infection
Polyphemusin II-Derived Peptide (T140), a *CXCR4* inhibitor, shows high inhibitory activity against HIV-1 entry and the inhibitory effect on the binding of an anti-CXCR4 monoclonal antibody (12G5) to CXCR4 .

HY-P1102A

TC14012 TFA	CXCR HIV	Infection Cancer
TC14012 TFA, a serum-stable derivative of T140, is a selective and peptidomimetic *CXCR4* antagonist with an IC₅₀ of 19.3 nM. TC14012 TFA is a potent *CXCR7* agonist with an EC₅₀ of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 TFA has anti-HIV activity and anti-cancer activity .

HY-P1104

FC131	CXCR HIV	Infection
FC131 is a potent *CXCR4* antagonist. FC131 inhibits [ ¹²⁵I]-SDF-1 binding to CXCR4 with an IC₅₀ of 4.5 nM. FC131 has anti-HIV activity .

HY-P1682

Balixafortide POL6326	CXCR Arrestin	Cancer
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic *CXCR4* antagonist with an IC₅₀ < 10 nM. Balixafortide shows 1000-fold selective for *CXCR4* than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-131374

TN14003	CXCR	Cancer
TN14003 is a *CXCR4* inhibitor. TN14003 has antitumor activity .

HY-P1682A

Balixafortide TFA 1 Publications Verification POL6326 TFA	CXCR Arrestin	Cancer
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic *CXCR4* antagonist with an IC₅₀ < 10 nM. Balixafortide TFA shows 1000-fold selective for *CXCR4* than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-P10427

DV1	CXCR HIV	Infection
DV1 is a selective antagonist for CXC chemokine receptor 4 (CXCR4). DV1 exhibits antiviral activity by blocking HIV-1 entry through the CXCR4 co-receptor. DV1 is stable in rat plasma and exhibits good pharmacokinetic characteristics in rat models .

HY-P10429

RCP168	CXCR	Infection
RCP168 is a highly selective and affinity *CXCR4* receptor antagonist (IC₅₀=5 nM). RCP168 has a stronger ability than natural chemical factors to inhibit the entry of HIV-1 (human immunodeficiency virus type 1) into host cells via *CXCR4* receptors. RCP168 inhibits HIV-1 infection by blocking viral binding sites or inducing receptor internalization. RCP168 can be used to analyze the interaction between *CXCR4* receptor and other chemical factor receptors .

HY-P0171

Motixafortide 2 Publications Verification BKT140 (4-fluorobenzoyl); BL-8040; TF14016	CXCR	Endocrinology Cancer
Motixafortide (BKT140 4-fluorobenzoyl) is a novel *CXCR4* antagonist with an IC₅₀ vakue of ～1 nM.

HY-P10415

EPI-X4 hSA(408–423) peptide	CXCR	Infection Inflammation/Immunology Cancer
EPI-X4 (hSA408–423 peptide) is an antagonist for C-X-C motif chemokine receptor 4 (CXCR4) with IC₅₀ of 8.6 μM. EPI-X4 blocks the CXCL12-mediated signaling, inhibits chemokine-mediated migration and invasion of leukemia cell. EPI-X4 exhibits anti-inflammatory activity in mouse model. EPI-X4 exhibits antiviral activity against CXCR4-tropic HIV with IC₅₀ of 8.6 μM .

HY-P4109

vMIP-II (1-21) NT21MP; V1 peptide	CXCR	Inflammation/Immunology Cancer
vMIP-II (1-21) (NT21MP) is an inhibitor of *CXCR4. vMIP-II (1-21) interacts broadly with CC and CXC chemokine receptors. vMIP-II (1-21) inhibits CXCR4* by competing with 125I-SDF-1R for binding sites (IC₅₀=190 nM) .

HY-P7061

ALX 40-4C	CXCR Apelin Receptor (APJ)	Infection Endocrinology
ALX 40-4C is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a K_i of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC₅₀ of 2.9 μM.

HY-P7061A

ALX 40-4C Trifluoroacetate 1 Publications Verification	Apelin Receptor (APJ) CXCR	Infection Endocrinology
ALX 40-4C Trifluoroacetate is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a K_i of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC₅₀ of 2.9 μM.

HY-P4109A

vMIP-II (1-21) TFA NT21MP TFA; V1 peptide TFA	CXCR	Inflammation/Immunology Cancer
vMIP-II (1-21) (NT21MP) TFA is an inhibitor of *CXCR4. vMIP-II (1-21) TFA interacts broadly with CC and CXC chemokine receptors. vMIP-II (1-21) TFA inhibits CXCR4* by competing with 125I-SDF-1R for binding sites (IC₅₀=190 nM) .

HY-153549

Pentixafor	Radionuclide-Drug Conjugates (RDCs) CXCR	Others
Pentixafor is a peptide that targets *CXCR4*. Pentixafor is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for positron emission tomography (PET) imaging .

HY-125567

Antileukinate	CXCR	Inflammation/Immunology
Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury .

HY-P10444

DOTA Conjugated JM#21 derivative 7	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney .

HY-P4111

Peptide R	CXCR	Cancer
Peptide R, a cyclic peptide, is a specific *CXCR4* antagonist. Peptide R shows outstanding capacities to profoundly remodel the tumor stroma. Peptide R has the potential for tumor research .

HY-W104862

4-Amino-D-phenylalanine 4-NH2-d-Phe	CXCR	Inflammation/Immunology
4-Amino-D-phenylalanine ([D-Phe(4-NH2)), a cyclic pentapeptide, inhibits CXCL12 binding to *CXCR4* in FC131, with an IC₅₀ of 0.1 μM .

HY-P10333

LIH383	Peptides	Neurological Disease Inflammation/Immunology
LIH383 is an agonist of ACKR3 (CXCR7) (EC₅₀=0.61 nM). LIH383 efficiently induces the recruitment of β-arrestin to ACKR3 but does not trigger typical G protein signaling .

HY-P4095

NoxaBH3	CXCR	Cancer
NoxaBH3 is a cysteine-based cross-linked peptide with increased cell permeability and higher inhibitory activity against Mcl-1. NoxaBH3 binds to the endogenous *CXCR4* ligand to produce ubiquitin-Noxabh3 conjugate. NoxaBH3 is then delivered to cancer cells .

HY-P3612

CTCE-0214	CXCR	Inflammation/Immunology
CTCE-0214 is a chemokine CXC receptor 4 (CXCR4) agonist, SDF-1α (stromal cell-derived factor-1α) peptide analog. CTCE-0214 shows anti-inflammatory activity, and can be used in inflammation sepsis and systemic inflammatory syndromes research .

HY-W019787

BAM-12P	Opioid Receptor CXCR	Neurological Disease
BAM-12P, an endogenous opioid peptide, is a novel pro-Met-enkephalin. BAM-12P can activate human κ-opioid receptor (hKOR) with an EC₅₀ of 101 nM and a pEC₅₀ of 6.99. BAM-12P is a ligand for *CXCR7* with an EC₅₀ of 175 nM .

HY-P4911

SDF-1α (human)	CXCR	Cardiovascular Disease
SDF-1α (human) is a mononuclear cells chemoattractant that can bind to *CXCR4*. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) can be used in cardiovascular disease research .

HY-P4911A

SDF-1α (human) (TFA)	CXCR	Cardiovascular Disease
SDF-1α (human) TFA is a mononuclear cells chemoattractant that can bind to *CXCR4*. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) TFA can be used in cardiovascular disease research .

HY-P4846

Ac-Pro-Gly-Pro-OH	CXCR	Inflammation/Immunology
Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and can be used as *CXCR2* agonist. Ac-Pro-Gly-Pro-OH elicits bactericidal activity and inhibits lung inflammation, reducing immune cell apoptosis. Ac-Pro-Gly-Pro-OH enhances the production of type 1 cytokines (IFN-γ and IL-12) but inhibits the production of proinflammatory cytokines. Ac-Pro-Gly-Pro-OH has the potential for the research of sepsis .

HY-P0172A

ATI-2341 TFA 2 Publications Verification	CXCR	Inflammation/Immunology Endocrinology Cancer
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .

HY-P0172

ATI-2341	CXCR	Inflammation/Immunology Endocrinology Cancer
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 *(CXCR4)*, which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .

Cat. No.	Product Name	Target	Research Area